Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis

Frederik Banch Clausen*, Klaus Rieneck, Grethe Risum Krog, Birgitte Suhr Bundgaard, Morten Hanefeld Dziegiel

*Corresponding author for this work
2 Citations (Scopus)

Abstract

RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis. Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.

Original languageEnglish
Title of host publicationPrenatal Diagnosis
EditorsBrynn Levy
Number of pages13
PublisherHumana Press
Publication date2019
Pages347-359
ISBN (Print)978-1-4939-8887-7
ISBN (Electronic)978-1-4939-8889-1
DOIs
Publication statusPublished - 2019
SeriesMethods in Molecular Biology
Volume1885
ISSN1064-3745

Keywords

  • Antenatal prophylaxis
  • Anti-D
  • Cell-free fetal DNA
  • Hemolytic disease of the fetus and newborn
  • Noninvasive RHD typing
  • Real-time PCR

Fingerprint

Dive into the research topics of 'Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis'. Together they form a unique fingerprint.

Cite this